SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays.

Autor:	Walker GJ; Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031, Australia.; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia., Naing Z; Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia., Ospina Stella A; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia., Yeang M; Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031, Australia.; Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia., Caguicla J; Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia., Ramachandran V; Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia., Isaacs SR; Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031, Australia., Agapiou D; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia., Bull RA; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia., Stelzer-Braid S; Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031, Australia.; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia., Daly J; Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, VIC 3004, Australia., Gosbell IB; Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, VIC 3004, Australia.; School of Medicine, Western Sydney University, Penrith, NSW 2747, Australia., Hoad VC; Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, VIC 3004, Australia., Irving DO; Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, VIC 3004, Australia.; Faculty of Health, University of Technology, Sydney, NSW 2007, Australia., Pink JM; Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, VIC 3004, Australia., Turville S; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia., Kelleher AD; Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia., Rawlinson WD; Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031, Australia.; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.; Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia.; School of Biotechnology and Biomolecular Sciences, Faculty of Science, University of New South Wales, Sydney, NSW 2052, Australia.
Jazyk:	angličtina
Zdroj:	Viruses [Viruses] 2021 Feb 04; Vol. 13 (2). Date of Electronic Publication: 2021 Feb 04.
DOI:	10.3390/v13020247
Abstrakt:	Serological testing for SARS-CoV-2-specific antibodies provides important research and diagnostic information relating to COVID-19 prevalence, incidence and host immune response. A greater understanding of the relationship between functionally neutralising antibodies detected using microneutralisation assays and binding antibodies detected using scalable enzyme immunoassays (EIA) is needed in order to address protective immunity post-infection or vaccination, and assess EIA suitability as a surrogate test for screening of convalescent plasma donors. We assessed whether neutralising antibody titres correlated with signal cut-off ratios in five commercially available EIAs, and one in-house assay based on expressed spike protein targets. Sera from recovered patients or convalescent plasma donors who reported laboratory-confirmed SARS-CoV-2 infection ( n = 200), and negative control sera collected prior to the COVID-19 pandemic ( n = 100), were assessed in parallel. Performance was assessed by calculating EIA sensitivity and specificity with reference to microneutralisation. Neutralising antibodies were detected in 166 (83%) samples. Compared with this, the most sensitive EIAs were the Cobas Elecsys Anti-SARS-CoV-2 (98%) and Vitros Immunodiagnostic Anti-SARS-CoV-2 (100%), which detect total antibody targeting the N and S1 antigens, respectively. The assay with the best quantitative relationship with microneutralisation was the Euroimmun IgG. These results suggest the marker used (total Ab vs. IgG vs. IgA) and the target antigen are important determinants of assay performance. The strong correlation between microneutralisation and some commercially available assays demonstrates their potential for clinical and research use in assessing protection following infection or vaccination, and use as a surrogate test to assess donor suitability for convalescent plasma donation.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.